Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nifedipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 5/20 | 0.90 |
| ▸ | CACNA1F known ✓ | O60840 | 2/20 | 0.90 |
| ▸ | CACNA1D known ✓ | Q01668 | 2/20 | 0.90 |
| ▸ | CACNA1S known ✓ | Q13698 | 2/20 | 0.90 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.90 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.90 |
| ▸ | MAPT | P10636 | 6/20 | 0.90 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.90 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.90 |
| ▸ | TSHR | P16473 | 4/20 | 0.90 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.90 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.90 |
| ▸ | LMNA | P02545 | 3/20 | 0.90 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.90 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.90 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.90 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.90 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nifedipine SCHEMBL9322551 | 0.95 | ADORA3 (0.90) | ADORA3CYP1A2CYP3A4MAPTCYP2C9 | |
| Nifedipine SCHEMBL29349595 | 0.95 | ADORA3 (1.00) | ADORA3CYP1A2CYP3A4MAPTCYP2C9 | |
| Nifedipine SCHEMBL3968 | 0.95 | ADORA3 (1.00) | ADORA3CYP1A2CYP3A4MAPTCYP2C9 | |
| Nifedipine SCHEMBL1172946 | 0.95 | ADORA3 (1.00) | ADORA3CYP1A2CYP3A4MAPTCYP2C9 | |
| Nifedipine SCHEMBL5694031 | 0.94 | ADORA3 (0.97) | ADORA3CYP1A2CYP3A4MAPTCYP2C9 | |
| Nifedipine SCHEMBL8851397 | 0.94 | ADORA3 (0.97) | ADORA3CYP1A2CYP3A4MAPTCYP2C9 | |
| Nifedipine SCHEMBL27076589 | 0.94 | ADORA3 (0.97) | ADORA3CYP1A2CYP3A4MAPTCYP2C9 | |
| Nifedipine SCHEMBL3858071 | 0.94 | ADORA3 (0.97) | ADORA3CYP1A2CYP3A4MAPTCYP2C9 | |
| Nifedipine SCHEMBL8851402 | 0.94 | ADORA3 (0.97) | ADORA3CYP1A2CYP3A4MAPTCYP2C9 | |
| Nifedipine SCHEMBL27961697 | 0.94 | ADORA3 (0.97) | ADORA3CYP1A2CYP3A4MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0240484-B1 | PHARMACEUTICAL COMPOSITION AND ITS PREPARATION | Burghart, Kurt, Dr. (DE) | 1992-01-15 | — | — | EP | claimed |
| US-4869899-A | AEROSOL FORMULATION FOR NIFEDIPINE | BURGHART WALTER (AT) | 1989-09-26 | — | — | US | claimed |
| CN-109010278-A | A kind of preparation method of Nifedipine sustained-release preparation | 刘丽 | 2018-12-18 | — | — | CN | disclosed |
| EP-2519261-B1 | Oral liquid pharmaceutical composition of nifedipine | REIG JOFRE S A LAB (ES) | 2013-11-27 | — | — | EP | disclosed |
| US-20120289553-A1 | ORAL LIQUID PHARMACEUTICAL COMPOSITION OF NIFEDIPINE | LABORATORIO REIG JOFRE, S.A. (ES) | 2012-11-15 | — | — | US | disclosed |
| EP-2519261-A1 | ORAL LIQUID PHARMACEUTICAL COMPOSITION OF NIFEDIPINE | Laboratorio Reig Jofre S.A. (ES) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011080246-A1 | ORAL LIQUID PHARMACEUTICAL COMPOSITION OF NIFEDIPINE | LABORATORIO REIG JOFRÉ, S.A. (ES) | 2011-07-07 | — | — | WO | disclosed |
| US-4869899-A | AEROSOL FORMULATION FOR NIFEDIPINE | BURGHART WALTER (AT) | 1989-09-26 | — | — | US | disclosed |
| US-4869899-A | AEROSOL FORMULATION FOR NIFEDIPINE | BURGHART WALTER (AT) | 1989-09-26 | — | — | US | disclosed |
| WO-1987005211-A1 | PHARMACEUTICAL PREPARATION AND PROCESS FOR PRODUCING THE SAME | BURGHART KURT | 1987-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289553-A1 | ORAL LIQUID PHARMACEUTICAL COMPOSITION OF NIFEDIPINE | CACNA1C, CACNA1D, CACNA1G | CACNA1C 1/4885CACNA1F 4/4885CACNA1D 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.